Literature DB >> 25274805

Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome.

Christian Selinger1, Natasa Strbo2, Louis Gonzalez2, Lauri Aicher1, Jeffrey M Weiss1, G Lynn Law1, Robert E Palermo3, Monica Vaccari4, Genoveffa Franchini4, Eckhard R Podack2, Michael G Katze5.   

Abstract

Using whole-blood transcriptional profiling, we investigated differences in the host response to vaccination and challenge in a rhesus macaque AIDS vaccine trial. Samples were collected from animals prior to and after vaccination with live, irradiated vaccine cells secreting the modified endoplasmic reticulum chaperone gp96-Ig loaded with simian immunodeficiency virus (SIV) peptides, either alone or in combination with a SIV-gp120 protein boost. Additional samples were collected following multiple low-dose rectal challenges with SIVmac251. Animals in the boosted group had a 73% reduced risk of infection. Surprisingly, few changes in gene expression were observed during the vaccination phase. Focusing on postchallenge comparisons, in particular for protected animals, we identified a host response signature of protection comprised of strong interferon signaling after the first challenge, which then largely abated after further challenges. We also identified a host response signature, comprised of early macrophage-mediated inflammatory responses, in animals with undetectable viral loads 5 days after the first challenge but with unusually high viral titers after subsequent challenges. Statistical analysis showed that prime-boost vaccination significantly lowered the probability of infection in a time-consistent manner throughout several challenges. Given that humoral responses in the prime-boost group were highly significant prechallenge correlates of protection, the strong innate signaling after the first challenge suggests that interferon signaling may enhance vaccine-induced antibody responses and is an important contributor to protection from infection during repeated low-dose exposure to SIV.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25274805      PMCID: PMC4248781          DOI: 10.1128/CVI.00455-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  44 in total

1.  A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins.

Authors:  B K Cho; D Palliser; E Guillen; J Wisniewski; R A Young; J Chen; H N Eisen
Journal:  Immunity       Date:  2000-03       Impact factor: 31.745

2.  HIV-1 Nef impairs MHC class II antigen presentation and surface expression.

Authors:  P Stumptner-Cuvelette; S Morchoisne; M Dugast; S Le Gall; G Raposo; O Schwartz; P Benaroch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

3.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

Authors:  A Le Bon; G Schiavoni; G D'Agostino; I Gresser; F Belardelli; D F Tough
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

4.  Human immunodeficiency virus type 1 infection modulates the interleukin (IL)-1beta and IL-6 responses of human macrophages to CD40 ligand stimulation.

Authors:  A Bergamini; F Bolacchi; B Bongiovanni; V Colizzi; G Cappelli; I Uccella; M Cepparulo; M Capozzi; G Mancino; G Rocchi
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

5.  PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques.

Authors:  Ravi Dyavar Shetty; Vijayakumar Velu; Kehmia Titanji; Steven E Bosinger; Gordon J Freeman; Guido Silvestri; Rama Rao Amara
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

6.  Control of the interferon-induced 68-kilodalton protein kinase by the HIV-1 tat gene product.

Authors:  S Roy; M G Katze; N T Parkin; I Edery; A G Hovanessian; N Sonenberg
Journal:  Science       Date:  1990-03-09       Impact factor: 47.728

7.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

8.  Gamma interferon-mediated inflammation is associated with lack of protection from intravaginal simian immunodeficiency virus SIVmac239 challenge in simian-human immunodeficiency virus 89.6-immunized rhesus macaques.

Authors:  Kristina Abel; Lisa La Franco-Scheuch; Tracy Rourke; Zhong-Min Ma; Veronique De Silva; Beth Fallert; Laurel Beckett; Todd A Reinhart; Christopher J Miller
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.

Authors:  T C VanCott; F R Bethke; D S Burke; R R Redfield; D L Birx
Journal:  J Immunol       Date:  1995-10-15       Impact factor: 5.422

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  6 in total

1.  Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Authors:  Monica Vaccari; Shari N Gordon; Slim Fourati; Luca Schifanella; Namal P M Liyanage; Mark Cameron; Brandon F Keele; Xiaoying Shen; Georgia D Tomaras; Erik Billings; Mangala Rao; Amy W Chung; Karen G Dowell; Chris Bailey-Kellogg; Eric P Brown; Margaret E Ackerman; Diego A Vargas-Inchaustegui; Stephen Whitney; Melvin N Doster; Nicolo Binello; Poonam Pegu; David C Montefiori; Kathryn Foulds; David S Quinn; Mitzi Donaldson; Frank Liang; Karin Loré; Mario Roederer; Richard A Koup; Adrian McDermott; Zhong-Min Ma; Christopher J Miller; Tran B Phan; Donald N Forthal; Matthew Blackburn; Francesca Caccuri; Massimiliano Bissa; Guido Ferrari; Vaniambadi Kalyanaraman; Maria G Ferrari; DeVon Thompson; Marjorie Robert-Guroff; Silvia Ratto-Kim; Jerome H Kim; Nelson L Michael; Sanjay Phogat; Susan W Barnett; Jim Tartaglia; David Venzon; Donald M Stablein; Galit Alter; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  Nat Med       Date:  2016-05-30       Impact factor: 53.440

2.  Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques.

Authors:  S Abigail Smith; Katie M Kilgore; Sudhir Pai Kasturi; Bali Pulendran; Eric Hunter; Rama R Amara; Cynthia A Derdeyn
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

3.  Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication.

Authors:  Huanbin Xu; Anne-Marie Andersson; Emeline Ragonnaud; Ditte Boilesen; Anders Tolver; Benjamin Anderschou Holbech Jensen; James L Blanchard; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Allan Randrup Thomsen; Jan Pravsgaard Christensen; Ronald S Veazey; Peter Johannes Holst
Journal:  EBioMedicine       Date:  2017-03-08       Impact factor: 8.143

Review 4.  Recombinant protein vaccines, a proven approach against coronavirus pandemics.

Authors:  Jeroen Pollet; Wen-Hsiang Chen; Ulrich Strych
Journal:  Adv Drug Deliv Rev       Date:  2021-01-07       Impact factor: 17.873

5.  Induction of SARS-CoV-2 Protein S-Specific CD8+ T Cells in the Lungs of gp96-Ig-S Vaccinated Mice.

Authors:  Eva Fisher; Laura Padula; Kristin Podack; Katelyn O'Neill; Matthew M Seavey; Padmini Jayaraman; Rahul Jasuja; Natasa Strbo
Journal:  Front Immunol       Date:  2021-01-26       Impact factor: 7.561

6.  Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4+ and CD8+ T-Cell Responses.

Authors:  Ulrike Sauermann; Antonia Radaelli; Nicole Stolte-Leeb; Katharina Raue; Massimiliano Bissa; Carlo Zanotto; Michael Krawczak; Matthias Tenbusch; Klaus Überla; Brandon F Keele; Carlo De Giuli Morghen; Sieghart Sopper; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2017-11-14       Impact factor: 6.549

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.